Response
Open Access
- 23 February 2015
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (5) , djv056
Abstract
We appreciate the comments of Donna Graham et al. on our recent article ( 1 ). The first issue they raise concerns the use of an adjuvant treated patient cohort for risk scores intended to assist in decisions regarding whether or not such treatment should be administered at all. While we agree with this perception, we also contend that prognostic signatures so far have failed to provide information on likelihood of response to drugs in the adjuvant setting, which implies that they represent inherent prognostic groups, the outcome of which is not improved by therapy. This is an issue in itself, but beyond the scope of our paper. In absence of such evidence, a treated patient cohort is potentially as informative on the prognostic groups.Keywords
This publication has 4 references indexed in Scilit:
- Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression DataJNCI: Journal of the National Cancer Institute, 2014
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon CancerJNCI: Journal of the National Cancer Institute, 2012
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded TissueJournal of Clinical Oncology, 2011
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesBreast Cancer Research, 2008